Chronic subdural Hematoma
Conditions
Interventions
simple drilling group:routine neurosurgical monitoring and treatment after drilling
the atorvastatin group:oral atorvastatin 20mg (1 tablet) Qd for 28 days.
combine atorvastatin and dexamethasone group:On days 1-14, atorvastatin 20mg (1 tablet) Qd and dexamethasone 0.75mg (1 tablet) Tid
on days 15-21, atorvastatin 20mg (1 tablet) Qd and dexamethasone 0.75mg (1 tablet) Bid
On days 22-28, atorvastatin 20 mg (1 tablet) Qd and dexamethasone 0.75 mg (1 tablet) Qd.
Sponsors
Haining People's Hospital, Zhejiang Province
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Aged >= 18 years and < 90 years, no gender restriction; (2) Within 72 hours before enrollment in the experiment, CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma (MRI scan is warranted if diagnosis is difficult); a single unilateral hematoma should be greater than 10ml; (3) No cerebral hernia; (4) Chronic cranial pressure or cerebral compression manifestations, such as: headache, vomiting, optic disc edema, mental Intellectual disability, epilepsy, neurolocalization signs, etc .; (5) No severe systemic disease that constitutes a contraindication to surgery, including those with severe coagulopathy; (6) Those who can follow up for more than 3 months after surgery; (7) All patients sign informed consent.
Exclusion criteria
Exclusion criteria: (1) There are severe abnormalities in heart, lung, liver, and kidney function, which affect the overall prognosis of patients; (2) Postoperative coagulopathy or liver dysfunction that is not related to surgery, as well as suffering from other disease may interfere the study; (3) Head injury during follow-up period; (4) Contraindications for the use of atorvastatin and dexamethasone; (5) Poor blood glucose control, and fasting blood glucose continued to be greater than 10mmol / L; (6) History of oral statins within 4 weeks before the trial; (7) History of oral steroid hormones within 4 weeks before the trial; (8) Female patients during pregnancy or lactation; (9) Poor compliance and unable to complete the trial according to the research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematoma recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication rate;Neurological recovery; | — |
Countries
China
Contacts
Public ContactChen Weiliang
Haining People's Hospital
Outcome results
None listed